Cessation of tyrosine kinase inhibitors in patients with chronic-phase chronic myelogenous leukemia following durable complete molecular response: A single center facing the dilemma

Anticancer Research

Volumn 33, Issue 8, 2013, Pages 3509-3514

  Iliakis, Theodoros ^a   Papadopoulou, Vasiliki ^a   Diamantopoulos, Panagiotis T ^a   Panayiotidis, Panayiotis ^b   Zervakis, Konstantinos ^a   Giannakopoulou, Nefeli ^a   Tilimidos, Gerassimos ^a   Angelopoulou, Maria ^c   Siakantaris, Marina P ^a   Pangalis, Gerassimos ^d   Mantzourani, Marina ^a   Variami, Eleni ^a   Viniou, Nora Athina ^a  

^a LAIKO GENERAL HOSPITAL   (Greece)

^b First Propaedeutic Department of Internal Medicine   (Greece)

^c UNIVERSITY OF ATHENS   (Greece)

^d Medical Centre Psychiko   (Greece)

Author keywords

Chronic phase CML; Complete molecular response; TKI

Indexed keywords

DASATINIB; HYDROXYUREA; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT ALPHA INTERFERON;

ADULT; AGED; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG COST; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEALTH CARE SYSTEM; HUMAN; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SWELLING; TREATMENT RESPONSE;

CHRONIC-PHASE CML; COMPLETE MOLECULAR RESPONSE; TKI;

ADULT; AGED; FEMALE; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 84883308127     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S and Sawyers CL: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344: 1031-1037, 2001.
2. Deininger M, O'Brien SG, Guilhot F, Goldman JM, Hochhaus A and Hughes TP: International Randomized Study of Interferon vs. STI571 (IRIS) 8-year follow up: Sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 114: 1126, 2009.
3. Hochhaus A, Shah NP, Cortes J, Baccarani M, Bradley-Garelik MB, Dejardin D and Kantarjan H: Dasatinib versus imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): DASISION 3-year follow-up. J Clin Oncol: 30: 6504, 2012.
4. Larson RA, Hochhaus A, Hughes TP, Clark RE, Etienne G, Kim DW, Flinn IW, Kurokawa M, Moiraghi B, Yu R, Blakesley RE, Gallagher NJ, Saglio G and Kantarjian HM: Nilotinib versus imatinib in patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 36-month follow-up. Leukemia 26: 2197-2203, 2012.
5. Pavey T, Hoyle M, Ciani O, Crathorne L, Jones-Hughes T, Cooper C, Osipenko L, Venkatachalam M, Rudin C, Ukoumunne O, Garside R and Anderson R: Dasatinib, nilotinib and standarddose imatinib for the first-line treatment of chronic myeloid leukaemia: Systematic reviews and economic analyses. Health Technol Assess 16: 1-277, 2012.
6. Khoury HJ, Cortes JE, Kantarjan HM, Gambacorti-Passerini C, Baccarani M, Kim DW, Zaritskey A, Countouriotis A, Besson N, Leip E, Kelly V and Brummendorf TH: Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood 119: 3403-3412, 2012.
7. Cortes J, Lipton JH, Rea D, Digumarti R, Chuah C, Nanda N, Benichou AC, Craig AR, Michallet M, Nicolini FE, Kantarjian H; Omacetaxine 202 Study Group: Phase II study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood 120: 2573-2580, 2012.
8. Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, O'Hare T, Hu S, Narasimhan NI, Rivera VM, Clackson T, Turner CD, Haluska FG, Druker BJ, Deininger MW and Talpaz M: Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 367: 2075-2088, 2012.
9. Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Bartley PA, Slader C, Field C, Dang P, Filshie RJ, Mills AK, Grigg AP, Melo JV and Hughes TP: Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia 24: 1719-1724, 2010.
10. Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F, Legros L, Charbonnier A, Guerci A, Varet B, Etienne G, Reiffers J, Rousselot P; Intergroupe Francais des Leucemies Myeloides Chroniques: Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least two years: the prospective, multicentre, Stop IMatinib (STIM) trial. Lancet Oncol 11: 1029-1035, 2010.
11. Cortes J, O'Brien S and Kantarjian H: Discontinuation of imatinib therapy after achieving a molecular response. Blood 104: 2204-2205, 2004.
12. Mauro MJ, Druker BJ and Maziarz RT: Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission. Leukemia Res 28: S71-S73, 2004.
13. Merante S, Orlandi E, Bernasconi P, Calatroni S, Boni M and Lazzarino M: Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation. Haematologica 90: 979-981, 2005.
14. Breccia M, Diverio D, Pane F, Nanni M, Russo E, Biondo F, Frustaci A, Gentilini F and Alimena G: Discontinuation of imatinib therapy after achievement of complete molecular response in a Ph(+) CML patient treated while in long lasting complete cytogenetic remission (CCR) induced by interferon. Leukemia Res 30: 1577-1579, 2006.
15. Rousselot P, Huguet F, Rea D, Legros L, Cayuela JM, Maarek O, Blanchet O, Marit G, Gluckman E, Reiffers J, Gardembas M and Mahon FX: Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than two years. Blood 109: 58-60, 2007.
16. Verma D, Kantarjian H, Jain N and Cortes J: Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha. Leuk Lymphoma 49: 1399-1402, 2008.
17. Kiguchi T, Tauchi T and Ohyashiki K: Molecular relapse of chronic myeloid leukemia after discontinuation of imatinib mesylate for maintaining complete molecular response for more than two years. Rinsho Ketsueki 50: 52-54, 2009 (Article in Japanese).
18. Goh HG, Kim YJ, Kim DW, Kim HJ, Kim SH, Jang SE, Lee J, Kim D, Kim WS, Park SH and Kweon IY: Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy. Leuk Lymphoma 50: 944-951, 2009.
19. Takahashi N, Kyo T, Maeda Y, Sugihara T, Usuki K, Kawaguchi T, Usui N, Okamoto S, Ohe Y, Ohtake S, Kitamura K, Yamamoto M, Teshima H, Motoji T, Tamaki T, Sawada K and Ohyashiki K: Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia. Haematologica 97: 903-906, 2012.
20. Yhim HY, Lee NR, Song EK, Yim CY, Jeon SY, Shin S, Kim JA, Kim HS, Cho EH and Kwak JY: Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response. Leuk Res 36: 689-693, 2012.
21. Ross DM, Bartley PA, Goyne J, Morley AA, Seymour JF and Grigg AP: Durable complete molecular remission of chronic myeloid leukemia following dasatinib cessation, despite adverse disease features. Haematologica 96: 1720-1722, 2011.
22. Rea D, Rousselot P, Nicolini FE, Legros L, Tulliez M, Giraudier S, Cony-Makhoul P, Guilhot F and Mahon FX: Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia patients with stable undetectable BCR-ABL transcripts: results from the French CML group (FILMC). Blood 118: 604, 2011.
23. Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini FE, Legros L, Charbonnier A, Guerci A, Varet BR, Etienne G, Reiffers J and Rousselot P: Discontinuation of imatinib in patients with chronic myeloid leukemia who have maintained complete molecular response: Update Results of the STIM Study. Blood 118: 603, 2011.
24. Mahon FX, Delbrel X, Cony-Makhoul P, Faberes C, Boiron JM, Barthe C, Bilhou-Nabera C, Pigneux A, Marit G and Reiffers J: Follow-up of Complete Cytogenetic Response in patients with Chronic Myeloid Leukemia after cessation of interferon-alpha. J Clin Oncol 20: 214-220, 2002.
25. Mahon FX, Fort MP, Etienne G, Marit G, Milpied G, Pigneux A, Cony-Makhoul P and Reiffers J: Interferon alpha alone is able to cure chronic myeloid leukemia in a small subset of patients despite the persistence of leukemic cells: Experience of long follow-up after treatment discontinuation. Blood 116: 2299, 2010.
26. Kumari A, Brendel C, Hochhaus A, Neubauer A and Burchert A: Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib. Blood 119: 530-539, 2012.
27. Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L and Holyoake TL: Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99: 319-325, 2002.
28. Bhatia R, Holtz M, Niu N, Gray R, Snyder DS, Sawyers CL, Arber DA, Slovak ML and Forman SJ: Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 101: 4701-4707, 2003.
29. Chu S, McDonald T, Lin A, Chakraborty S, Huang Q, Snyder DS and Bhatia R: Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood 118: 5565-5572, 2011.
30. Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW and Druker BJ: Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest 121: 396-409, 2011.
31. Hamilton A, Helgason GV, Schemionek M, Zhang B, Myssina S, Allan EK, Nicolini FE, Muller-Tidow C, Bhatia R, Brunton VG, Koschmieder S and Holyoake TL: Chronic myeloid leukemia stem cells are not dependent on BCR-ABL kinase activity for their survival. Blood 119: 1501-1510, 2012.
32. Guilhot F, Druker B, Larson RA, Gathmann I, So C, Waltzman R and O'Brien SG: High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: Results from the International Randomized Study of Interferon and STI571 (IRIS) trial. Haematologica 94: 1669-1675, 2009.
33. Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, Goldman JM, Muller MC, Radich JP, Rudoltz M, Mone M, Gathmann I, Hughes TP, Larson RA; IRIS Investigators: Sixyear follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 23: 1054-1061, 2009.
34. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA; IRIS Investigators: Five-year follow-up for patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355: 2408-2417, 2006.
35. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F, Hochhaus A, Horowitz M, Hughes T, Kantarjian H, Larson R, Radich J, Simonsson B, Silver RT, Goldman J and Hehlmann R; European LeukemiaNet: Chronic myeloid leukemia: An update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 27: 6041-6051, 2009.
36. NCCN CML guidelines v.3.2013, www.nccn.org
37. Mattison R and Larson RA: Discontinuing imatinib in CML: Don't try this at home. Leuk Lymphoma 50: 868-870, 2009.